The PREFERS Stockholm study is designed to deeply characterize new-onset heart failure patients to identify novel biomarkers and pathophysiological mechanisms, particularly for HFpEF.
No takes yet. Share an insight, caveat, or question.
May identify actionable HFpEF biomarkers; leaves open validation and therapeutic translation.
Linde et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: